- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
High-grade Ta tumors unresponsive to BCG progress fast and may be classified as High risk
Recent research found that All HG Ta tumors have an inferior response to BCG and increased rates of progression and should be considered as high risk. The study was published in 'The Journal of Urology,2022.'
Guidelines differ concerning the risk stratification of Ta tumors, specifically high-grade (HG) Ta tumors. Hence researchers performed a study to investigate the response of all Ta tumors to bacillus Calmette-Guérin (BCG) and collate the response rates based on the European Association of Urology (EAU) classification, as intermediate- (IR) or high-risk (HR).
For this, researchers conducted an institutional review of all patients who received adequate BCG from 2000–2018. Later patients were stratified according to the EAU 2021 prognostic risk factors. The newly proposed adverse risk factors were also included.
Results:
- Patients with Ta tumors were stratified into IR and HR.
- 37 (16%) had IR low-grade (LG), Ta, 92 (40%) had IR HG Ta and 101 (44%) had HR HG Ta tumors.
- BCG unresponsiveness developed in 13% of HR HG Ta tumors and 14% of IR HG Ta tumors compared to 0.0% of IR LG Ta tumors (p=0.003).
- While no patients with IR LG Ta tumors progressed, progression rates were similar in HR HG Ta and IR HG Ta tumors (≥T2: 5.9% and 6.5%; T1: 13% and 13%, respectively).
- Rates of recurrence, BCG unresponsiveness, and progression were similar, irrespective of several EAU risk factors present (p=0.9, p=0.8, and p=0.9, respectively).
Thus, the researchers concluded that regardless of EAU risk stratification All HG Ta tumors have an inferior response to BCG and increased rates of progression compared to IR LG Ta tumors. They also added that as EAU clinical risk factors did not improve the prediction of oncologic outcomes among HG Ta patients who received adequate BCG, all HG tumors should be considered as high risk.
For the full article, click here: https://doi.org/10.1097/JU.0000000000002678
Bree KK, Hensley PJ, Lobo N, et al. All High-Grade Ta Tumors Should Be Classified as High Risk: Bacillus Calmette-Guérin Response in High-Grade Ta Tumors [published online ahead of print, 2022 Jun 30]. J Urol. 2022;101097JU0000000000002678.
BDS, MDS
Dr.Niharika Harsha B (BDS,MDS) completed her BDS from Govt Dental College, Hyderabad and MDS from Dr.NTR University of health sciences(Now Kaloji Rao University). She has 4 years of private dental practice and worked for 2 years as Consultant Oral Radiologist at a Dental Imaging Centre in Hyderabad. She worked as Research Assistant and scientific writer in the development of Oral Anti cancer screening device with her seniors. She has a deep intriguing wish in writing highly engaging, captivating and informative medical content for a wider audience. She can be contacted at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751